RBI
IOVA icon

Raiffeisen Bank International’s Iovance Biotherapeutics IOVA Stock Holding History

Raiffeisen Bank International’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.32K Hold
2,000
– – ﹤0.01% 723
2026
Q1 		$7.02K Hold
2,000
– – ﹤0.01% 769
2025
Q4 		$4.66K Hold
2,000
– – ﹤0.01% 759
2025
Q3 		$4.34K Buy
+2,000
New +$4.72K ﹤0.01% 769

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Raiffeisen Bank International's IOVA Position: Q2 2026 in Review

Raiffeisen Bank International held its Iovance Biotherapeutics (IOVA) position steady in Q2 2026 at 380,000 shares worth $1.6M. The position accounts for 0.02% of the portfolio, ranked #347.

Raiffeisen Bank International first reported a position in IOVA in Q4 2024 and has held it in 7 quarters since. 109 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Raiffeisen Bank International held 380,000 shares of Iovance Biotherapeutics worth $1.6M as of Q2 2026.
  • Raiffeisen Bank International left its Iovance Biotherapeutics share count unchanged in Q2 2026.
  • Iovance Biotherapeutics made up 0.02% of Raiffeisen Bank International's portfolio in Q2 2026, its #347 holding.
  • Raiffeisen Bank International first reported a position in Iovance Biotherapeutics in Q4 2024 and has held it in 7 quarters since.
  • 109 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Raiffeisen Bank International's 13F filing for Q2 2026, filed 3 Aug 2026.